CLINICA BAVIERA SA financials
CLINICA BAVIERA SA
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
959800CR1BA43ZK65T94 Financial statements
(EUR, as reported — unscaled; 113 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €262.6M | €224.9M |
| Other income | €588.1K | €459.3K |
| Employee benefits expense | €99.5M | €85.9M |
| Raw materials & consumables used | €33.6M | €29.2M |
| Depreciation & amortisation | €20.9M | €17.0M |
| Operating profit (EBIT) | €55.7M | €50.0M |
| Net finance income / (cost) | €333.5K | -€346.3K |
| Finance costs | €1.2M | €571.7K |
| Profit before tax | €56.0M | €49.7M |
| Income tax expense | €14.9M | €12.9M |
| Profit for the year | €41.1M | €36.7M |
| — attributable to owners | €40.2M | €36.0M |
| — attributable to NCI | €930.7K | €763.4K |
| Total comprehensive income | €40.8M | €37.5M |
| Cash flow statement | ||
| Net cash from operating activities | €62.5M | €57.8M |
| Net cash from investing activities | -€20.9M | -€44.3M |
| Purchase of PP&E (capex) | €26.5M | €22.7M |
| Net cash from financing activities | -€39.7M | -€24.4M |
| Dividends paid | €25.9M | €13.6M |
| Proceeds from borrowings | €7.2M | €0 |
| Repayments of borrowings | €2.5M | €2.0M |
| Lease liability payments | €9.3M | €8.5M |
| Balance sheet | ||
| Total assets | €211.7M | €178.6M |
| Non-current assets | €164.0M | €120.9M |
| Property, plant & equipment | €122.7M | €99.1M |
| Intangible assets & goodwill | €28.3M | €14.6M |
| Current assets | €47.7M | €57.7M |
| Inventories | €3.3M | €2.5M |
| Trade & other receivables | €4.2M | €3.0M |
| Cash & equivalents | €10.1M | €8.3M |
| Total equity | €98.4M | €92.3M |
| — attributable to owners | €96.9M | €91.0M |
| Non-controlling interests | €1.4M | €1.3M |
| Non-current liabilities | €62.9M | €41.1M |
| Current liabilities | €50.4M | €45.3M |
| Trade & other payables | €17.2M | €15.5M |
| Deferred tax liabilities | €914.0K | €513.8K |
| Derived metrics | ||
| Free cash flow | €36.0M | €35.1M |
| Operating margin | 21.2% | 22.2% |
| Net margin | 15.7% | 16.3% |
| Return on equity | 41.8% | 39.8% |
| Cash conversion ratio | 1.52× | 1.57× |
| Capex coverage | 2.36× | 2.55× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €20.9M | €17.0M |
| Adjustments For Decrease Increase In Other Operating Receivables | €217.3K | -€433.4K |
| Adjustments For Decrease Increase In Trade Account Receivable | €63.4K | -€17.4K |
| Adjustments For Fair Value Gains Losses | -€1.2M | -€66.6K |
| Adjustments For Finance Costs | €1.2M | €571.7K |
| Adjustments For Finance Income | -€296.5K | -€151.3K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | -€247.2K | -€311.9K |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€27.1K | €26.7K |
| Adjustments For Provisions | €446.7K | €697.1K |
| Basic Earnings Loss Per Share From Continuing Operations | €2.47 | €2.21 |
| Comprehensive Income Attributable To Noncontrolling Interests | €958.9K | €784.8K |
| Comprehensive Income Attributable To Owners of Parent | €39.9M | €36.7M |
| Current Payables On Social Security and Taxes Other Than Income Tax | €4.1M | €3.9M |
| Current Tax Assets Current | €153.3K | €0 |
| Current Tax Liabilities | €3.6M | €3.5M |
| Current Unsecured Bank Loans Received and Current Portion of Noncurrent Unsecured Bank Loans Received | €1.9M | €2.0M |
| Deferred Tax Assets | €1.9M | €1.4M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €1.57 | — |
| Dividends Recognised As Distributions To Owners Per Share | €1.57 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€119.2K | €0 |
| Equity and Liabilities | €211.7M | €178.6M |
| Finance Income | €296.5K | €151.3K |
| Gains Losses On Disposals of Other Noncurrent Assets | €1.2M | €66.6K |
| Gains Losses On Disposals of Property Plant and Equipment | €27.1K | -€26.7K |
| Gains Losses On Exchange Differences On Translation Before Tax | €36.1K | €7.4K |
| Gains Losses On Exchange Differences On Translation Net of Tax | -€351.7K | -€999 |
| Gains Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Before Tax | €67.9K | €1.1M |
| Income Tax Relating To Financial Assets Measured At Fair Value Through Other Comprehensive Income | €17.0K | €269.8K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €0 | -€23.0K |
| Income Taxes Paid Refund Classified As Financing Activities | -€13.1M | -€11.6M |
| Increase Decrease In Cash and Cash Equivalents | €1.8M | -€10.9M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Transactions With Owners | -€34.8M | -€13.6M |
| Increase Decrease Through Transfers and Other Changes Equity | €56.8K | €0 |
| Increase Decrease Through Treasury Share Transactions | -€8.9M | €4.6K |
| Intangible Assets Other Than Goodwill | €8.7M | €2.7M |
| Interest Paid Classified As Financing Activities | €181.1K | €106.3K |
| Interest Received Classified As Investing Activities | €296.5K | €151.3K |
| Investment Accounted For Using Equity Method | €58.3K | €92.5K |
| Issued Capital | €1.6M | €1.6M |
| Noncurrent Portion of Noncurrent Unsecured Bank Loans Received | €5.3M | €503.0K |
| Other Adjustments To Reconcile Profit Loss | €335.0K | €4.2K |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | €11.1M | €0 |
| Other Comprehensive Income | -€300.7K | €740.1K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €0 | -€92.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€300.7K | €809.1K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | -€69.0K |
| Other Current Assets | €1.1M | €465.7K |
| Other Current Financial Assets | €28.4M | €42.9M |
| Other Current Financial Liabilities | €20.7M | €18.0M |
| Other Equity Interest | €507.6K | €0 |
| Other Expense By Nature | €56.6M | €45.4M |
| Other Longterm Provisions | €5.2M | €3.9M |
| Other Noncurrent Financial Assets | €2.3M | €3.0M |
| Other Noncurrent Financial Liabilities | €51.5M | €36.2M |
| Other Nonfinancial Liabilities | €2.6M | €2.1M |
| Other Reserves | €58.3M | €47.7M |
| Other Shortterm Provisions | €267.8K | €343.3K |
| Other Work Performed By Entity and Capitalised | €3.1M | €2.1M |
| Payments To Acquire Or Redeem Entitys Shares | €10.2M | €706.5K |
| Payments To Suppliers For Goods and Services | -€1.8M | €2.5M |
| Proceeds From Sale Or Issue of Treasury Shares | €1.4M | €711.1K |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €30.6M | €18.7M |
| Purchase of Financial Instruments Classified As Investing Activities | €14.2M | €40.5M |
| Receivables From Taxes Other Than Income Tax | €341.8K | €548.3K |
| Reserve of Exchange Differences On Translation | -€347.7K | €0 |
| Reserve of Gains and Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income | €903.3K | €884.4K |
| Share of Profit Loss of Associates Accounted For Using Equity Method | -€17.0K | -€14.6K |
| Share Premium | €4.9M | €4.9M |
| Treasury Shares | €9.1M | €109.9K |
Methodology
Every line item above is a fact tagged in CLINICA BAVIERA SA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.